Phase II, 2nd Line Melanoma - RAND Monotherapy
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks
Melanoma
DRUG: Anti-CD137 (4-1BB) (BMS-663513)
Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate, every 6 weeks starting at week 12 after randomization
Safety profiles, throughout the study|Disease response rate, end of study|Disease control rate, end of study|1-year survival, end of study|Pharmacokinetics, throughout the study|Pharmacodynamics, throughout the study|Biomarkers, throughout the study
The main purpose of this study is to estimate the proportion of patients with a type of skin cancer called melanoma who are progression free, (that is, the cancer has not gotten substantially worse), when treated with Anti-CD137 (4-1BB) (BMS-663513) at 0.1 mg/kg, 1 mg/kg or 5 mg/kg every 3 weeks or 1 mg/kg every 6 weeks